ANI Pharmaceuticals ANIP 深 滬
等待開盤 09-25 09:30:00 美东时间
74.04
-0.390
-0.52%
華盛通- 最 高75.37
- 今 開74.00
- 成交量 33.93万股
- 最 低 73.6859
- 昨 收 74.43
- 總市值 17.01亿
- 52周最高 97.00
- 市盈率 靜 22.27
- 換手率 1.48%
- 52周最低 69.58
- 委 比 -75.73%
- 總股本 2297.04万
- 歷史最高 99.50
- 量 比 0.53
- 振 幅 2.26%
- 歷史最低 0.80
- 每 手 1
- 風險率 5.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®. "The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execu...
09-23 18:56
ANI Pharmaceuticals to Present at September Investor Conferences
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, and executives will participate in fireside chats at three upcoming investor conferences: the 2026 Wells Fargo Healthcare Conference on September 10, 2026, at 1:30 p.m. ET; the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 7:00 a.m. ET; and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 12:00 p.m. ET. Webcasts fo...
09-03 10:55
ANI Pharmaceuticals reshapes board to advance rare disease strategy
The latest update is out from ANI Pharmaceuticals ( ($ANIP) ). On August 19, 20...
08-24 19:48
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
ANI Pharmaceuticals appoints Henry Gosebruch to its Board of Directors, leveraging his 30+ years of experience in biopharmaceutical strategy, business development, and finance to accelerate its transformation into a leading Rare Disease company. Gosebruch, formerly CEO of Lakefront Biotherapeutics and AbbVie's Chief Strategy Officer, will support ANI's growth initiatives. Samy Shanmugam resigns from the Board but remains in his executive role.
08-24 10:55
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
08-08 02:26
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:25
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:21
ANI Pharmaceuticals Affirms FY2026 Adj EPS Guidance of $9.19-$9.69 vs $9.45 Est; Affirms FY2026 Sales Guidance of $1.080B-$1.140B vs $1.119B Est
ANI Pharmaceuticals (NASDAQ:ANIP) affirms FY2026 Adj EPS guidance from $9.19-$9.69 to $9.19-$9.69 vs $9.45 analyst estimate. Affirms FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.080 billion-$1.140 billion vs $1.119 billion estimate.
08-07 18:53
